IP Library Granted Patent US 9,694,100
Granted Patent B2
US 9,694,100 · App. 13/514,945 · Granted Jul 4, 2017

Enzymatic wound debriding compositions with enhanced enzymatic activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,100
App. No.
13/514,945
Granted
Jul 4, 2017
Kind
B2
Abstract

The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.

Claims (36)

1. An anhydrous enzymatic wound debriding composition comprising:

(a) a hydrophilic dispersed phase comprising PEG 400 and collagenase; and

(b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase;

wherein the amount of PEG 400 is 10-30% w/w of the composition,

wherein the composition is anhydrous, and

wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin.

2. The anhydrous enzymatic wound debriding composition of claim 1 , wherein the hydrophobic base is petrolatum.

3. The anhydrous enzymatic wound debriding composition of claim 1 , wherein the amount of PEG 400 is 13-27% w/w of the composition.

4. The anhydrous enzymatic wound debriding composition of claim 3 , wherein the amount of PEG 400 is 20% w/w of the composition.

5. An anhydrous enzymatic wound debriding composition comprising:

(a) a hydrophilic dispersed phase comprising PEG 600 and collagenase; and

(b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase;

wherein the amount of PEG 600 is 20-40% w/w of the composition,

wherein the composition is anhydrous, and

wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin.

6. The anhydrous enzymatic wound debriding composition of claim 5 , wherein the hydrophobic base is petrolatum.

7. The anhydrous enzymatic wound debriding composition of claim 5 , wherein the amount of PEG 600 is 23-37% w/w of the composition.

8. The anhydrous enzymatic wound debriding composition of claim 7 , wherein the amount of PEG 600 is 30% w/w of the composition.

9. An anhydrous enzymatic wound debriding composition comprising:

(a) a hydrophilic dispersed phase comprising Poloxamer 124 and collagenase; and

(b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase;

wherein the amount of Poloxamer 124 is 20-40% w/w of the composition,

wherein the composition is anhydrous, and

wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin.

10. The anhydrous enzymatic wound debriding composition of claim 9 , wherein the hydrophobic base is petrolatum.

11. The anhydrous enzymatic wound debriding composition of claim 9 , wherein the amount of Poloxamer 124 is 23-37% w/w of the composition.

12. The anhydrous enzymatic wound debriding composition of claim 11 , wherein the amount of Poloxamer 124 is 30% w/w of the composition.

13. The anhydrous enzymatic wound debriding composition of claim 1 , wherein the composition is a liquid.

14. The anhydrous enzymatic wound debriding composition of claim 1 , wherein the composition is a semi-solid.

15. The anhydrous enzymatic wound debriding composition of claim 1 , wherein the composition is sterile.

16. The anhydrous enzymatic wound debriding composition of claim 5 , wherein the composition is a liquid.

17. The anhydrous enzymatic wound debriding composition of claim 5 , wherein the composition is a semi-solid.

18. The anhydrous enzymatic wound debriding composition of claim 5 , wherein the composition is sterile.

19. The anhydrous enzymatic wound debriding composition of claim 9 , wherein the composition is a liquid.

20. The anhydrous enzymatic wound debriding composition of claim 9 , wherein the composition is a semi-solid.

21. The anhydrous enzymatic wound debriding composition of claim 9 , wherein the composition is sterile.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2018
From: SHI, LEI; JOVANOVIC, ALEKSA; AUST, DUNCAN
To: HEALTHPOINT, LTD.
Reel/Frame 047703/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2013
From: HEALTHPOINT, LTD.
To: SMITH & NEPHEW, INC.
Reel/Frame 030014/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2012
From: SHI, LEI; JOVANOVIC, ALEKSA; AUST, DUNCAN
To: HEALTHPOINT, LTD.
Reel/Frame 028715/0497 →